
Nicola Ferrari/LinkedIn
Aug 12, 2025, 05:26
Nicola Ferrari: 50-Year Odyssey from Hybridomas to Modern Antibody Cancer Therapies
Nicola Ferrari, Director of Translational Science Lead for Respiratory and Immunology at AstraZeneca, shares a post on LinkedIn:
“Fifty years of monoclonals: the past, present and future of antibody therapeutics
This Review focuses on the 50-year odyssey from the advent of hybridoma technology in 1975 to the present era of antibody therapeutics and their clinical application to targeting B cells and HER2+ cancers.
- In 1975, Köhler and Milstein invented hybridoma technology for the generation of murine monoclonal antibodies with predetermined antigen-binding specificity.
- The transformative impact of hybridoma technology over the past 50 years is hard to overstate. Indeed, hybridoma provided a foundation that has led to at least 212 approved antibody therapeutics to date that have benefited millions of patients.
- Most antibody therapeutics are approved for indications in oncology (48%), or in autoimmunity and inflammatory diseases (25%). Almost all current antibody therapeutics are approved for delivery either by i.v. infusion (~63%), s.c. injection (~25%) or both i.v. and s.c. (8%).
- Antibody therapeutics have been dominated from the outset by monospecific IgG, which represent ~74% of currently approved antibodies.
- Beyond IgG, antibody therapeutics have blossomed into multiple alternative formats, including bispecific antibodies and antibody–drug conjugates. Additionally, antibody fragments have been developed as stand-alone therapeutics and to target cell therapies, notably chimeric antigen receptor T cells.”
Title: Fifty years of monoclonals: the past, present and future of antibody therapeutics
Journal: Nature Reviews Immunology
Authors: Andrew C. Chan, Greg D. Martyn, Paul J. Carter
More posts featuring antibody therapies on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 12, 2025, 08:00
Aug 12, 2025, 04:55
Aug 12, 2025, 04:26
Aug 11, 2025, 22:32
Aug 11, 2025, 21:07